Phase 3 CERVINO Trial Shows Etentamig Significantly Improves Response Rate and Progression-Free Survival in Relapsed/Refractory Myeloma (https://www.myeloma.org/news-events/multiple-myeloma-news/phase-3-cervino-trial-results)

Source URL: https://www.myeloma.org/news-events/multiple-myeloma-news/phase-3-cervino-trial-results